The Point of Care (PoC) molecular diagnostics market is forecasted to hit USD 5,295 Million by 2025. Then, it is likely to grow to USD 13,733.8 Million by 2035 with a CAGR of 10% over time. Things driving this growth include more people with long-term illnesses, bigger need for home tests, and the government backing fast testing solutions. These elements all play a role in moving the industry forward.
The Point of Care (PoC)molecular diagnostics marketshould grow a lot from 2025 to 2035. This rise comes from the need for fast and correct disease tests, more cases of infections, and new health ideas. POC tests let doctors check patients right away on the spot, cutting wait times and helping sick people faster. New tools like tiny fluid testers, CRISPR tech, and smart AI tools are also helping this market grow more.
Market Metrics
| Metric | Value |
|---|---|
| Market Size (2025E) | USD 5,295 Million |
| Market Value (2035F) | USD 13,733.8 Million |
| CAGR (2025 to 2035) | 10% |
Explore FMI!
Book a free demo
North America looks to lead the Point of Care (PoC)molecular diagnostics market. This is due to strong healthcare systems, high use of quick testing methods, and more money going to study diseases. The US and Canada help a lot because more people want to find diseases early, there are older people, and good rules helpPOC tests grow.
Key drivers are more lung infections, more personalized medicine, and big investments in biotech firms making new test solutions. Plus, home tests and telemedicine increase market reach.
Europe controls a big part of the Point of Care (PoC)molecular diagnostics market. Germany, the UK, France, and Italy are driving this growth. This region sees a lot of attention on testing that’s done outside central labs. Strict rules make sure tests are accurate. More money is being spent on smart tech in this field.
Quick and easy-to-move molecular tests for infections, cancer checks, and tracking resistance to drugs are becoming more popular. The European Union is working to improve readiness for pandemics and make diagnostics more accessible, pushing market growth further.
The Asia-Pacific region will likely see the most growth in the Point of Care (PoC)molecular diagnostics market. This is due to more people knowing about healthcare, more money spent on diagnostic tech, and better medical services in country areas.
Nations like China, India, Japan, and South Korea help the region grow. China has a strong biotech area, India has a bigger diagnostic market, and Japan has improved in AI diagnostics. These help the market grow. Also, governments are pushing for cheap and easy-to-get diagnostics for diseases, which boosts use even more.
High Cost of Advanced POC Diagnostics and Regulatory Hurdles
Though the Point of Care (PoC)molecular diagnostics marketrapidly expands, it faces several hurdles. The pricey advanced diagnostic tools could hinder use in settings with fewer resources. Moreover, tough rules for approving molecular tests make market entry and growth difficult.
Problems with interoperability and the need for uniform testing methods also block wide adoption. Additionally, worries about data privacy and blending AI-driven diagnostic tools into current healthcare systems need solutions.
Technological Advancements, Telemedicine Integration, and Emerging Markets
The market has big growth chances. AI tools for testing and mobile diagnostic platforms are key areas. Combining quick diagnostics with telemedicine opens new ways to manage diseases from afar.
Healthcare is growing in new markets. Focus on being ready for pandemics will increase the need for handy diagnostic tools. More funds are going into molecular testing for cancer and genetic issues, not just infections.
Compact, cheap, and sensitive tools for disease detection are becoming more common. This will help in catching diseases early, making it easier to diagnose in many health settings.
From 2020 to 2024, the point-of-care (PoC) molecular diagnostics market grew a lot. New fast test tech helped, also a need for health care close by, and COVID-19. PoCtests give correct results fast, which made them popular in clinics, hospitals, and homes. As more people learned about catching diseases early, and with more diseases showing up, the market grew more. But, rules, high pricetag on these diagnostic tools, and supply chain problems limited how widely they were used.
Looking forward to 2025 to 2035, the PoC molecular testing market will see big changes. Expect AI to be a big part of it. Small lab-on-a-chip tools will become common. Cloud-based tests will make sharing info easy. Personalized medicine will grow. More use of tests that check many things at once will happen.
Wearable test devices will become more normal and help the market grow. Tests will get cheaper and more automated. Healthcare providers and test companies will work more closely. This will make tests easier to get and use, even where resources are few.
Market Shifts: A Comparative Analysis (2020 to 2024 vs. 2025 to 2035)
| Market Shift | 2020 to 2024 |
|---|---|
| Regulatory Landscape | Compliance with evolving healthcare regulations and emergency use authorizations. |
| Technological Advancements | Development of rapid PCR-based POC tests. |
| Industry Applications | Primarily used in infectious disease testing (COVID-19, influenza, STIs). |
| Adoption of Smart Equipment | Limited digital integration, standalone POC devices. |
| Sustainability & Cost Efficiency | High costs associated with advanced molecular diagnostics. |
| Data Analytics & Predictive Modeling | Basic test result interpretation. |
| Production & Supply Chain Dynamics | Reliance on centralized manufacturing hubs and global supply chains. |
| Market Growth Drivers | Demand driven by pandemic-related testing and early disease detection. |
| Market Shift | 2025 to 2035 |
|---|---|
| Regulatory Landscape | Implementation of standardized global regulatory frameworks supporting decentralized diagnostics. |
| Technological Advancements | AI-powered diagnostics, lab-on-a-chip innovations, and integration with telemedicine platforms. |
| Industry Applications | Expansion into oncology, genetic testing, antimicrobial resistance monitoring, and chronic disease management. |
| Adoption of Smart Equipment | Increased use of IoT -connected diagnostic tools with real-time cloud-based monitoring. |
| Sustainability & Cost Efficiency | Development of cost-effective, portable, and eco-friendly diagnostic solutions. |
| Data Analytics & Predictive Modeling | AI-driven predictive analytics for early disease detection and treatment optimization. |
| Production & Supply Chain Dynamics | Shift towards localized manufacturing, automated production, and supply chain resilience strategies. |
| Market Growth Drivers | Growth fueled by advancements in precision medicine, home diagnostics, and increased healthcare accessibility. |
The Point of Care (PoC)molecular diagnostics marketin the USA is growing fast because people want quick and correct disease checks. More and more are using handy test tools, and tech for these tests is getting better. The USA FDA and CLIA check that these POC test tools work right and are safe.
Now, more are usingPCR-based PoC tests. There's a big need for tests on infections like COVID-19, flu, STDs, and breathing problems. Tiny chip tech for labs is getting better, too. AI-based tests and POC tools that link to the cloud are changing things in big ways.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 10.2% |
The Point of Care (PoC)molecular diagnostics marketin the UK is growing. This is due to more money going into healthcare, a need for local diagnostic tools, and government help for finding diseases early. Approvals and use of products are controlled by groups like the MHRA and NICE.
Trends in the market include more home diagnostic kits, a higher need for PoCtests to handle antimicrobial resistance, and new tech in tiny diagnostic tools. Also, government plans for personal medicine are pushing the market to grow more.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 9.8% |
The Point of Care (PoC)molecular diagnostics marketin the EU is growing. This is due to more infectious diseases, use of quick tests in primary care, and strict EU rules. The EMA and IVDR keep the market steady.
Germany, France, and the Netherlands are ahead. They have strong government money for diagnostics. These countries useportable tests and improvedwearable devices more. Also,telemedicine and digital health make these POC tests easier to get.
| Country | CAGR (2025 to 2035) |
|---|---|
| European Union (EU) | 10.1% |
Japan’sPoint of Care (PoC)molecular diagnostics marketis growing fast. The rise is due to an aging population, many cases of long-term and infectious diseases, and strong government backing for health innovation. TheMinistry of Health, Labour and Welfare (MHLW)makes sure products are safe and work well.
Trends show more money going intosmart testing devices, a need for very sensitive and specific molecular tests, and new advances in tiny tech-driven PoCtests. Also, usingpoint-of-care gene tests for personal treatment plans is becoming more popular.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 10.3% |
South Korea's market for point-of-care molecular diagnostics is growing. More government money for biotech and diagnostics, more need for fast disease tests, and betterAI diagnostic tools help this growth. TheKorean Ministry of Food and Drug Safety watches over product approvals and quality.
New trends include using CRISPR-based tests, morewearable devices for diagnostics, and more home molecular test kits. Telehealth servicesare growing, which is helpingremote diagnostics be more popular.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 10.0% |
The Point of Care (PoC)molecular diagnostics marketis seeing strong growth. This growth is due to the need for quick disease detection, more infectious disease cases, and better diagnostic tools. Among the various products, assays and kits will have the biggest market share in 2025. They will account for about 52.7% of the market. This is because they are easy to use and are widely used in many healthcare settings. Also, people prefer fast and reliable diagnostic tools.
| Products & Services | Market Share (2025) |
|---|---|
| Assays & Kits | 52.7% |
Point-of-care molecular diagnostic assaysand kits help find germs and signs of diseases fast. They are very important for finding out if someone has an infection, cancer, or a genetic issue. Many people want them because diseases like COVID-19, flu, and TB are common. These tests are handy for far-away places and places with few resources. New tech like tiny fluid tools, CRISPR, and updated PCR tests help too.
Even with good things, there are some issues. The tests can be pricey, rules can be tricky, and not all tests work the same everywhere. But, new ideas like testing for many things at once, smart computer help, and online health tools should help this market grow even more.
Among various ways to check molecules, RT-PCR stays on top in 2025, having around 64.2% of the market. Its huge success is because It excels at detecting details and can detect minuscule amounts of virus in illness tests.
| Technology | Market Share (2025) |
|---|---|
| RT-PCR | 64.2% |
RT-PCR has been a top method in testing for a long time. It is crucial for COVID-19 tests, lung infections, cancer, and finding genetic issues. It is used often in labs, clinics, and even at home. More automation and smaller RT-PCR tools allow quick results. New and faster RT-PCR tools and PoC systems give answers in minutes, not hours.
Yet, some issues remain. The machines are pricey, sample steps can be tricky, and new quick test methods like CRISPR are rising. Thus, firms work to improve RT-PCR abilities. Adding AI for better results, using cloud for reports, and linking with NGS will boost RT-PCR efficiency and use in PoC tests.
The Point of Care (PoC)molecular diagnostics marketis growing because people want fast, good, and easy to carry tests for diseases, genes, and cancer. This market is pushed by new tech, more diseases, and more home tests. Companies are working on small PCR systems, CRISPR tests, and smart tools to make tests better, quicker, and easier to use. Big firms in medicine, biotech, and health tech are all adding to new ideas in quick tests, tiny fluid tech, and online-connected tests.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Abbott Laboratories | 20-24% |
| Cepheid (Danaher Corporation) | 16-20% |
| bioMérieux SA | 12-16% |
| Roche Diagnostics | 10-14% |
| QuidelOrtho Corporation | 6-10% |
| Other Companies (combined) | 30-40% |
| Company Name | Key Offerings/Activities |
|---|---|
| Abbott Laboratories | In 2024, launched next-generation molecular Po C platforms with real-time data sharing for infectious disease diagnostics. |
| Cepheid (Danaher Corporation) | In 2025, introduced high-speed PCR tests for rapid pathogen detection in decentralized healthcare settings. |
| bioMérieux SA | In 2024, expanded syndromic testing panels to improve early disease detection and antimicrobial stewardship. |
| Roche Diagnostics | In 2025, developed AI-integrated Po C diagnostic solutions for real-time patient monitoring and disease prediction. |
| QuidelOrtho Corporation | In 2024, enhanced portable molecular diagnostic platforms for home-based and remote testing applications. |
Key Company Insights
Abbott Laboratories (20-24%)
Abbott leads the POC molecular diagnostics market, offering highly automated, rapid, and reliable diagnostic platforms.
Cepheid (Danaher Corporation) (16-20%)
Cepheid specializes in fast and accurate molecular diagnostic tests, with a focus on infectious disease and genetic disorder detection.
bioMérieux SA (12-16%)
bioMérieux focuses on syndromic testing solutions, leveraging multiplex PCR technology for enhanced disease identification.
Roche Diagnostics (10-14%)
Roche pioneers AI-driven molecular diagnostics, ensuring greater diagnostic accuracy and predictive insights.
QuidelOrtho Corporation (6-10%)
QuidelOrtho provides compact, user-friendly molecular diagnostic tools, expanding access to remote and home-based testing.
Other Key Players (30-40% Combined)
Many health device firms, new biotech companies, and health care creators help advance affordable point-of-care tests, multi-diagnostic tools, and cloud-based systems. These groups push forward affordable and smart medical tech.These include:
The overall market size for the Point of Care (PoC) molecular diagnostics market was USD 5,295 Million in 2025.
The Point of Care (PoC) molecular diagnostics market is expected to reach USD 13,733.8 Million in 2035.
Increasing prevalence of infectious diseases, rising demand for rapid and accurate diagnostic solutions, advancements in portable diagnostic technologies, and growing adoption in decentralized healthcare settings will drive market growth.
The USA, Germany, China, Japan, and the UK are key contributors.
The polymerase chain reaction (PCR)-based segment is expected to lead due to its high sensitivity, accuracy, and rapid turnaround time.
AL Amyloidosis Therapeutics Market Growth and Analysis: 2025 to 2035
Carcinoid Tumor Syndrome Management Market Forecast & Analysis for 2025 to 2035
Cardiogenic Shock Treatment Market Analysis & Forecast for 2025 to 2035
Brain Tumor Drugs Market Forecast & Analysis: 2025 to 2035
Pigmented Lesion Treatment Market Growth - Trends & Forecast 2025 to 2035
The Metered Dose Inhalers Market is Segmented by Type, and End User from 2025 to 2035
Point-of-care Molecular Diagnostics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
